Roche/Chugai's alectinib gets first worldwide approval
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai has received its first approval worldwide for its second-generation oral anaplastic lymphoma kinase inhibitor alectinib, in Japan.